Patent ID: 9365521
Filing Date: 2016-06-14
CPC Classification: A61K,A61P,C07C,C07D

Claim Text:
1. A salt selected from: (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hem i-edisylate salt having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 23.12°, 6.00°, and 19.70°, wherein the peaks can vary by ±0.2 2θ; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine phosphate salt having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 19.27°, 25.06°, and 25.77°, wherein the peaks can vary by ±0.2 2θ; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine citrate salt having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 11.93°, 18.64°, and 24.52°, wherein the peaks can vary by ±0.2 2θ; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hem i-oxalate salt having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 6.34°, 21.69°, and 31.85°, wherein the peaks can vary by ±0.2 2θ; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine succinate salt having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 27.62°, 20.65°, and 15.64°, wherein the peaks can vary by ±0.2 2θ; and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine oxoglutarate salt having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 13.39°, 23.57°, and 21.22°, wherein the peaks can vary by ±0.2 2θ; and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine oxoglutarate salt solvate, having an X-ray powder diffraction pattern comprising peaks, in terms of 2θ, at 26.02°, 11.53°, and 22.65°, wherein the peaks can vary by ±0.2 2θ.